Drugs / enviomycin
enviomycin
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02365623 Background | Feb 2015 → Nov 2018 | multidrug-resistant tuberculosis | Janssen Pharmaceutical K.K. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | enviomycin | “anti-bacterial tuberculosis drugs (pyrazinamide [PZA], ethambutol [EB, EMB], streptomycin [SM], kanamycin [KM, KAN], enviomycin [EVM], ethionamide [TH], cycloserine [CS],...” NCT02365623 ↗ |
| Known as | Enviomicina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2146142 ↗ |
| Known as | Enviomycine | ChEMBL registry synonym — accepted as the source's own label CHEMBL2146142 ↗ |
| Known as | EVM | “enviomycin [EVM]” NCT02365623 ↗ |
| Known as | Tuberactinomycin n | ChEMBL registry synonym — accepted as the source's own label CHEMBL2146142 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL2146142 ↗ |